Award

The role of smooth muscle cell estrogen receptor alpha in aging-associated arterial stiffness

Description: Background: Arterial stiffness increases with age and is an independent risk factor for cardiovascular disease (CVD). Although arterial stiffness develops later in life in women than men, it develops at a faster rate and has a stronger association with CVD morbidity and mortality in women. Evidence supports a protective role of estrogen and estrogen receptor alpha (ERa) in premenopausal women, yet their roles have not been defined in the context of vascular aging. Based on preliminary data, we propose to test the novel hypothesis that unliganded smooth muscle cell (SMC)-ERa contributes to aging-associated arterial stiffness via repression of the vasoprotective angiotensin II type 2 receptor (AT2R) and subsequent increase in pro-fibrotic pathways downstream of AT2R. Methods: To investigate the role of SMC-ERa in aging-associated arterial stiffness in males and females, this proposal details experiments to complete the following three aims: 1) investigate the role of SMC-ERa in aging-associated arterial stiffness in vivo in young (3 mo.), middle-aged (12 mo.), and advanced age (18 mo.) male and female SMC-ERa-intact and SMC-ERa-knockout (KO) mice and in young (3 mo.) and middle-aged (12 mo.) female SMC-ERa-intact and SMC-ERa-KO mice who have undergone sham or ovariectomy procedure; 2) test the hypothesis in vitro that SMC-ERa regulates pro-fibrotic genes in an AT2R-dependent manner in human aortic SMC from young and aged men and women; and 3) test the in vivo therapeutic potential of chronic AT2R activation to prevent aging-associated arterial stiffness in middle-aged (12 mo.) male and female wildtype mice treated with either vehicle or NP-6A4, a novel AT2R agonist, for 4 weeks. In vivo arterial stiffness will be measured by aortic pulse wave velocity, intrinsic SMC stiffness will be measured by atomic force microscopy, and vascular fibrosis will be assessed with Masson’s trichrome staining. Aortic protein and gene expression of AT2R and downstream pro-fibrotic targets and serum sex hormones will be measured. Conclusions: Results from the proposed studies will have substantial clinical significance, both enhancing the basic understanding of molecular mechanisms of aging-associated arterial stiffness and providing support for innovative therapeutic treatments to improve CVD outcomes in postmenopausal women and men, thus supporting the AHA’s core mission to facilitate longer, healthier lives.
Amount: $144,600
Funding type: fellowship
Funder scheme: Postdoctoral Fellowship
Start date: 2024-01-01
End date: 2025-01-01
Investigator: Casey Turner (lead)
Field: Medicine
Funded outputs count: 6
Funder award ID: 24POST1192551
OpenAlex ID: G6893269673
2025 · Casey G. Turner, Rachel Kenney, et al. · American Journal of Physiology-Heart and Circulatory Physiology · 3
2025 · Casey G. Turner, Jennifer J. DuPont · American Journal of Physiology-Heart and Circulatory Physiology · 9
2025 · Casey G. Turner, Karla de Oliveira, et al. · Journal of Pharmacology and Experimental Therapeutics · 6
2024 · Casey G. Turner, Jennifer J. DuPont · American Journal of Physiology-Heart and Circulatory Physiology · 1
2024 · Casey G. Turner, Karla de Oliveira, et al. · The Journal of Cardiovascular Aging · 4